The biotech firm expects topline results soon for its menopause treatment ABCL635 after completing enrollment in the trial.
AbCellera announced $110M in upfront payments from new T-cell engager (TCE) collaborations, bolstering its cash position. The funds follow recent partnerships aimed at expanding its oncology pipeline beyond its core antibody discovery platform.
The company’s near-term focus remains on ABCL635, a candidate for moderate to severe menopausal hot flashes. Enrollment for the Phase II trial concluded, with topline data expected shortly, a critical catalyst for the stock. Analysts view the readout as pivotal for validating the asset’s commercial potential.
No immediate market reaction was disclosed, though the collaborations and upcoming data could influence investor sentiment in the biotech sector.